TP53 and acute myeloid leukemia: Because of this distinctive genomic and clinical profile, TP53-mutated MDS/AML has been recently classified separately as a unique disease entity in the World Health Organization (WHO-5) and International Classification Consortium (ICC) systems [4,5].